Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03418792 · ClinicalTrials.gov registry record · NA

Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx

A NA study of Head and Neck Cancer and Oropharynx Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT03418792 is a NA study of Head and Neck Cancer and Oropharynx Cancer that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 40 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03418792, a NA study of Head and Neck Cancer and Oropharynx Cancer, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The proposed study is an attempt to improve patient xerostomia (dry mouth) after definitive radiation therapy treatment for head and neck cancer. Xerostomia is a frequently experienced symptom for those receiving radiation therapies to the head and neck that persists after treatment, potentially indefinitely. It has been shown that stem/progenitor cells preferentially reside in large ducts of salivary glands and that these cells have the ability to repair radiation induced salivary damage. Current practice does not specifically attempt to spare these regions and considers the entire salivary gland to have equal importance and function. This study will involve the acquisition of pre-treatment MRI sialogram images which enable visualization of salivary ducts (using saliva itself as a contrast agent) that can then be avoided during radiation treatment planning. Saliva samples will also be collected at this time to quantify baseline saliva secretion and saliva characteristics. The primary objective will be to obtain patient reported outcomes (PRO) measure of xerostomia related symptoms for comparison with a historical cohort. Xerostomia symptom information will be obtained by use of a patient reported quality of life survey administered prior to treatment and at 6, 12, 18, and 24 months after treatment. The secondary objectives will be to quantitatively assess post-treatment changes in saliva secretion, salivary gland volume, and ductal visibility using MRI sialograms. The target sample size for this study is 40 patients. The investigator hypothesizes that reducing the dose to these stem cell containing salivary ducts will facilitate improvements in patient reported symptoms as well as improved recovery of salivary secretion, salivary gland volume, and intra-glandular ductal visibility using MRI sialograms.

Interventions

  • OTHER Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography

Study Locations (1)

North Carolina

  • University of North Carolina at Chapel Hill, Department of Radiation Oncology - Chapel Hill

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2018-03-08
Est. Completion 2023-05-02
Phase NA

What the Registry Record Tells You About NCT03418792

The ClinicalTrials.gov registry entry for NCT03418792 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (85% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography is the first listed.

NCT03418792 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT03418792 about?

NCT03418792 is a clinical study titled "Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx". The proposed study is an attempt to improve patient xerostomia (dry mouth) after definitive radiation therapy treatment for head and neck cancer. Xerostomia is a frequently experienced symptom for those receiving radiation therapies to the head and neck that persists after treatment, potentially ind...

What is the current status of trial NCT03418792?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2018-03-08. Estimated completion is 2023-05-02.

What conditions does trial NCT03418792 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Oropharynx Cancer, Xerostomia Due to Radiotherapy.

What interventions are being tested in trial NCT03418792?

The interventions under investigation include: Parotid-Sparing Head & Neck Radiation Guided by MRI Sialography (OTHER).

Who is sponsoring clinical trial NCT03418792?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03418792 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.